Current status of engineered T-cell therapy for synovial sarcoma. Review uri icon

Overview

abstract

  • Synovial sarcoma is a rare soft tissue sarcoma characterized by a t(X;18) translocation, which results in a SYT-SSX gene fusion. In the metastatic setting, chemotherapy has limited, durable efficacy prompting the necessity for new therapeutic modalities. One emerging new strategy involves T-cell-directed therapy such as tumor-infiltrating lymphocytes or the development of T cells that are genetically engineered to express a T-cell receptor against a cancer testis antigen. Of these approaches, engineered T cells that recognize NY-ESO-1 are the furthest along in development. Completed and on-going clinical trials have shown promise and there are efforts to continue to optimize the current approach.

publication date

  • September 1, 2016

Research

keywords

  • Chromosomes, Human, Pair 18
  • Immunotherapy, Adoptive
  • Lymphocytes, Tumor-Infiltrating
  • Receptors, Antigen, T-Cell
  • Recombinant Fusion Proteins
  • Sarcoma, Synovial
  • T-Lymphocytes

Identity

PubMed Central ID

  • PMC5618931

Scopus Document Identifier

  • 84981268317

Digital Object Identifier (DOI)

  • 10.2217/imt-2016-0026

PubMed ID

  • 27485079

Additional Document Info

volume

  • 8

issue

  • 9